中国基金报·2025-07-25 04:46Core Viewpoint - The article highlights a strong performance in the technology sector, particularly in artificial intelligence (AI) stocks, amidst a general market pullback in A-shares on July 25, 2023 [2][5][10]. Market Overview - On July 25, A-shares experienced a collective pullback, with the Shanghai Composite Index falling to 3593.38 points, down 0.34% [2]. - The trading volume in the Shanghai and Shenzhen markets reached 1.11 trillion yuan, a decrease of 94.5 billion yuan from the previous trading day, marking the 42nd consecutive day of trading volume exceeding 1 trillion yuan [4]. Sector Performance - The technology sector saw widespread gains, particularly in AI-related stocks, which were stimulated by recent news. Key concepts like multimodal models, Kimi, and ChatGPT led the rally [5][11][14]. - The medical sector also performed well, with the CRO (Contract Research Organization) concept experiencing significant gains [20][21]. - Conversely, the Hainan Free Trade Port concept stocks and major infrastructure sectors faced substantial declines [6]. Notable Stocks - AI application stocks showed remarkable performance, with companies like Yinsai Group hitting the 20% limit up, and others like CloudWalk Technology and EasyPoint Technology also showing strong gains [15][19]. - The medical sector saw notable increases, with companies like Nanwei Medical and Kangtai Medical achieving significant price jumps [21][22]. Upcoming Events - The World Artificial Intelligence Conference is set to take place on July 26, 2025, in Shanghai, with expectations of positive impacts on the AI sector due to the attendance of high-profile figures, including the Chinese Premier [16]. Policy and Economic Context - Recent policies, including the introduction of guidelines for AI-generated content, aim to foster innovation in the AI sector. Shanghai's AI industry saw a 29% year-on-year growth in the first quarter, with profits increasing by 65% [18]. - The National Medical Insurance Administration is actively promoting innovation in the medical field, which is expected to further boost the performance of medical stocks [23].